A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Participants With EGFR Mutation-Positive Metastatic NSCLC

Inclusion Criteria:

- Cytologically or histologically confirmed diagnosis of Stage IV NSCLC as defined by
the American Joint Committee on Cancer Staging Criteria for Lung Cancer (AJCC 7th
edition 2009).

- Eligible for first-line treatment with erlotinib based on documented evidence of tumor
harboring an activating EGFR mutation [exon 19 deletion or exon 21 (L858R)
substitution mutation].

- Mandatory provision of adequate archived stage IV NSCLC tissue samples or tissue
samples other than stage IV NSCLC may be acceptable (optional for part C).

- At least one measurable lesion.

- Life expectancy of at least 3 months.

Exclusion Criteria:

- Known T790M EGFR mutation (not applicable for Part C Period 2).

- Known leptomeningeal carcinomatosis, uncontrolled/unstable spinal cord compression, or
brain metastases.

- Serious illness or medical condition.

- Ongoing treatment with CYP3A4 inducers or strong inhibitors.

- Ongoing therapy with nonsteroidal anti-inflammatory drugs for more than 2 months.

- History of gross hemoptysis.

- Significant bleeding disorders.

- Radiologically documented evidence of major blood vessel invasion or encasement by
cancer.

- Radiographic evidence of intratumor cavitation.

- History of gastrointestinal perforation within last 6 months.

- History of bowel obstruction, inflammatory enteropathy or extensive intestinal
resection.

- History of any arterial thrombotic event within 6 months prior to enrollment.

- The participant has any known significant ophthalmologic abnormalities of the surface
of the eye.